Document is current
Any future updates will be listed below
-
Authors
Pærregaard, Simone Isling https://orcid.org/0000-0001-6879-0529
Wulff, Line https://orcid.org/0000-0002-7482-4569
Schussek, Sophie
Niss, Kristoffer
Mörbe, Urs https://orcid.org/0000-0001-8747-437X
Jendholm, Johan
Wendland, Kerstin https://orcid.org/0000-0001-9776-5437
Andrusaite, Anna T.
Brulois, Kevin F.
Nibbs, Robert J. B. https://orcid.org/0000-0002-8150-0044
Sitnik, Katarzyna https://orcid.org/0000-0002-6965-0322
Mowat, Allan McI https://orcid.org/0000-0001-9389-3079
Butcher, Eugene C. https://orcid.org/0000-0001-8786-7907
Brunak, Søren https://orcid.org/0000-0003-0316-5866
Agace, William W.
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R155-2014-4184)
Leona M. and Harry B. Helmsley Charitable Trust
Novo Nordisk Fonden (NNF22OC0071681)
- License Information
-
More Information
Article History
Received: 20 August 2021
Accepted: 6 April 2023
First Online: 21 April 2023
Competing interests
: SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S and managing board memberships in Proscion A/S and Intomics A/S. The remaining authors declare no competing interests.
